NCT01617005View on ClinicalTrials.gov

A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.

Trial Locations (1)

81000

Podgorica

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01617005 - A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs) | Biotech Hunter | Biotech Hunter